Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt N/A
ABT's Cash to Debt is ranked higher than
72% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ABT: N/A )
Ranked among companies with meaningful Cash to Debt only.
ABT' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.29 Max: 1.28
Current: N/A
0.05
1.28
Equity to Asset 0.51
ABT's Equity to Asset is ranked lower than
70% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ABT: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
ABT' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.44 Max: 0.59
Current: 0.51
0.37
0.59
Interest Coverage 17.38
ABT's Interest Coverage is ranked lower than
72% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 481.81 vs. ABT: 17.38 )
Ranked among companies with meaningful Interest Coverage only.
ABT' s Interest Coverage Range Over the Past 10 Years
Min: 4.91  Med: 10.93 Max: 18.07
Current: 17.38
4.91
18.07
F-Score: 7
Z-Score: 3.42
M-Score: -2.46
WACC vs ROIC
11.66%
12.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 14.05
ABT's Operating margin (%) is ranked higher than
82% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. ABT: 14.05 )
Ranked among companies with meaningful Operating margin (%) only.
ABT' s Operating margin (%) Range Over the Past 10 Years
Min: 8.81  Med: 16.06 Max: 20.27
Current: 14.05
8.81
20.27
Net-margin (%) 21.68
ABT's Net-margin (%) is ranked higher than
92% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. ABT: 21.68 )
Ranked among companies with meaningful Net-margin (%) only.
ABT' s Net-margin (%) Range Over the Past 10 Years
Min: 7.64  Med: 13.54 Max: 27.74
Current: 21.68
7.64
27.74
ROE (%) 24.04
ABT's ROE (%) is ranked higher than
94% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. ABT: 24.04 )
Ranked among companies with meaningful ROE (%) only.
ABT' s ROE (%) Range Over the Past 10 Years
Min: 9.78  Med: 21.49 Max: 28.49
Current: 24.04
9.78
28.49
ROA (%) 12.47
ABT's ROA (%) is ranked higher than
89% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -0.07 vs. ABT: 12.47 )
Ranked among companies with meaningful ROA (%) only.
ABT' s ROA (%) Range Over the Past 10 Years
Min: 4.68  Med: 8.77 Max: 12.12
Current: 12.47
4.68
12.12
ROC (Joel Greenblatt) (%) 39.43
ABT's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. ABT: 39.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 5.27  Med: 44.88 Max: 65.75
Current: 39.43
5.27
65.75
Revenue Growth (3Y)(%) -18.80
ABT's Revenue Growth (3Y)(%) is ranked lower than
88% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. ABT: -18.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.8  Med: 8.40 Max: 13.7
Current: -18.8
-18.8
13.7
EBITDA Growth (3Y)(%) -21.00
ABT's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. ABT: -21.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -30  Med: 4.60 Max: 31.5
Current: -21
-30
31.5
EPS Growth (3Y)(%) -28.10
ABT's EPS Growth (3Y)(%) is ranked lower than
85% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. ABT: -28.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -54  Med: 2.85 Max: 48.8
Current: -28.1
-54
48.8
» ABT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ABT Guru Trades in Q1 2015

Joel Greenblatt 41,573 sh (New)
First Eagle Investment 5,142,802 sh (+311.11%)
Jeremy Grantham 10,727,819 sh (+17.76%)
Paul Tudor Jones 9,300 sh (+13.29%)
Pioneer Investments 1,995,930 sh (+1.88%)
PRIMECAP Management 17,765,299 sh (+0.72%)
Diamond Hill Capital 8,106,888 sh (+0.45%)
John Buckingham 90,906 sh (+0.03%)
Tom Russo 85,400 sh (unchged)
Robert Olstein 179,000 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
George Soros 602,181 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Mason Hawkins Sold Out
Ray Dalio Sold Out
Mario Gabelli 65,287 sh (-0.08%)
Mairs and Power 353,724 sh (-0.87%)
Jeff Auxier 77,871 sh (-1.27%)
Ken Fisher 13,095 sh (-5.30%)
Richard Pzena 6,373,745 sh (-7.09%)
Murray Stahl 18,603 sh (-13.37%)
Dodge & Cox 32,068 sh (-13.49%)
Jim Simons 412,300 sh (-52.01%)
» More
Q2 2015

ABT Guru Trades in Q2 2015

Ray Dalio 28,457 sh (New)
Joel Greenblatt 1,043,293 sh (+2409.54%)
Paul Tudor Jones 13,700 sh (+47.31%)
First Eagle Investment 5,916,570 sh (+15.05%)
Ken Fisher 14,994 sh (+14.50%)
John Buckingham 91,559 sh (+0.72%)
Louis Moore Bacon 300,000 sh (unchged)
Tom Russo 85,400 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Robert Bruce 230,915 sh (unchged)
George Soros 602,181 sh (unchged)
Murray Stahl 18,603 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Jim Simons Sold Out
Jeff Auxier 77,821 sh (-0.06%)
PRIMECAP Management 17,737,310 sh (-0.16%)
Richard Pzena 6,340,115 sh (-0.53%)
Diamond Hill Capital 8,062,685 sh (-0.55%)
Dodge & Cox 31,268 sh (-2.49%)
Mairs and Power 341,838 sh (-3.36%)
Mario Gabelli 61,032 sh (-6.52%)
Pioneer Investments 1,861,927 sh (-6.71%)
Robert Olstein 159,000 sh (-11.17%)
Jeremy Grantham 9,499,219 sh (-11.45%)
» More
Q3 2015

ABT Guru Trades in Q3 2015

John Hussman 3,000 sh (New)
Jim Simons 1,348,400 sh (New)
Paul Tudor Jones 59,714 sh (+335.87%)
Ray Dalio 82,457 sh (+189.76%)
Joel Greenblatt 1,455,289 sh (+39.49%)
George Soros 731,481 sh (+21.47%)
Murray Stahl 21,503 sh (+15.59%)
First Eagle Investment 6,825,289 sh (+15.36%)
Robert Olstein 176,000 sh (+10.69%)
Diamond Hill Capital 8,385,413 sh (+4.00%)
Ken Fisher 15,254 sh (+1.73%)
Jeff Auxier 78,922 sh (+1.41%)
John Buckingham 91,905 sh (+0.38%)
Westport Asset Management 200,000 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Tom Russo 85,400 sh (unchged)
Dodge & Cox 30,268 sh (-3.20%)
PRIMECAP Management 16,677,764 sh (-5.97%)
Mairs and Power 319,343 sh (-6.58%)
Vanguard Health Care Fund 6,938,700 sh (-8.60%)
Richard Pzena 5,188,346 sh (-18.17%)
Jeremy Grantham 6,469,218 sh (-31.90%)
Pioneer Investments 1,213,173 sh (-34.84%)
Mario Gabelli 17,625 sh (-71.12%)
» More
Q4 2015

ABT Guru Trades in Q4 2015

Robert Olstein 201,000 sh (+14.20%)
Ken Fisher 17,286 sh (+13.32%)
Murray Stahl 22,503 sh (+4.65%)
Diamond Hill Capital 8,621,765 sh (+2.82%)
Dodge & Cox 30,268 sh (unchged)
Mario Gabelli 17,625 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Jeff Auxier 78,922 sh (unchged)
Tom Russo 85,400 sh (unchged)
Jim Simons Sold Out
John Hussman Sold Out
Pioneer Investments 1,212,972 sh (-0.02%)
PRIMECAP Management 16,643,039 sh (-0.21%)
John Buckingham 91,506 sh (-0.43%)
First Eagle Investment 6,671,344 sh (-2.26%)
Richard Pzena 4,861,129 sh (-6.31%)
Jeremy Grantham 5,653,313 sh (-12.61%)
Vanguard Health Care Fund 6,027,260 sh (-13.14%)
Ray Dalio 38,857 sh (-52.88%)
» More
» Details

Insider Trades

Latest Guru Trades with ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Abbott Laboratories

Mason Hawkins Comments on Abbott Laboratories - May 28, 2015

Abbott (ABT), a global healthcare company, reached our appraisal, resulting in a 120% return over our 4-year holding period. We are extremely appreciative of the value that CEO Miles White built for shareholders during our ownership.

From Mason Hawkins (Trades, Portfolio)’ Longleaf Partners Fund Q1 2015 Management Discussion.

Check out Mason Hawkins latest stock trades

Lountzis Asset Management Comments on Abbott Laboratories - Mar 21, 2014

ABBOTT LABORATORIES (NYSE:ABT) is a leading diversified healthcare company operating in the following areas: pharmaceuticals, diagnostics, nutritionals and medical products.



On January 1, 2013, Abbott consummated the separation of its research based pharmaceuticals business and distributed 100% of the outstanding shares of common stock of AbbVie to the holders of record of Abbott common shares that were issued and outstanding on December 12, 2012. Each Abbot shareholder received one share of AbbVie common stock for every share of Abbot common stock held. The Abbott shareholder also received cash in lieu of any fractional share of AbbVie common stock resulting from the distribution.



Abbott common shares now trade under ticker symbol "ABT" and shares of AbbVie common stock trade under ticker symbol "ABBV". The new Abbott is a diversified global healthcare company with several leading franchises. In 2012, the company generated sales of $21.5 billion from these four diverse business units: nutritionals 30%, medical products 25%, established pharmaceuticals 24% and diagnostics 20%.



Abbott has leading market share positions in several businesses including the number one market share in:



1. Worldwide Adult Nutrition and U.S. Pediatric Nutrition



2. Amino Acid Immunoassay Diagnostics and Blood Screening



3. Drug Eluting Stents and for



4. Lasik



Furthermore, Abbott, in addition to a broad portfolio of products and services, is geographically diverse with 29% of sales in the U.S., 30% in other developed markets and 40% in the more rapidly growing emerging markets. The current Chairman and CEO, Miles D. White, will continue in these positions for the new Abbott, focused upon several initiatives including expanding the company’s products into new geographic markets, developing new technologies and focusing on accelerating margin expansion and improving free cash flow.



The new Abbott generated 2013 revenue through its four segments of $21.9 billion with earnings per share of $2.01. We continue to hold the new Abbott and believe its product and geographic diversity, combined with its leadership positions in several areas, will enable the company to continue to grow and prosper.



From Lountzis Asset Management 2013 Annual Letter



Check out latest stock trades

Top Ranked Articles about Abbott Laboratories

Mason Hawkins Comments on Abbott Laboratories
Abbott (ABT), a global healthcare company, reached our appraisal, resulting in a 120% return over our 4-year holding period. We are extremely appreciative of the value that CEO Miles White built for shareholders during our ownership. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 12.40
ABT's P/E(ttm) is ranked higher than
85% of the 260 Companies
in the Global Medical Devices industry.

( Industry Median: 28.39 vs. ABT: 12.40 )
Ranked among companies with meaningful P/E(ttm) only.
ABT' s P/E(ttm) Range Over the Past 10 Years
Min: 5.78  Med: 10.12 Max: 35.05
Current: 12.4
5.78
35.05
Forward P/E 15.24
ABT's Forward P/E is ranked higher than
98% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 18.42 vs. ABT: 15.24 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.20
ABT's PE(NRI) is ranked higher than
62% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 27.40 vs. ABT: 22.20 )
Ranked among companies with meaningful PE(NRI) only.
ABT' s PE(NRI) Range Over the Past 10 Years
Min: 5.93  Med: 11.06 Max: 97.44
Current: 22.2
5.93
97.44
P/B 2.62
ABT's P/B is ranked lower than
52% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ABT: 2.62 )
Ranked among companies with meaningful P/B only.
ABT' s P/B Range Over the Past 10 Years
Min: 1.39  Med: 2.23 Max: 3.34
Current: 2.62
1.39
3.34
P/S 2.73
ABT's P/S is ranked higher than
82% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. ABT: 2.73 )
Ranked among companies with meaningful P/S only.
ABT' s P/S Range Over the Past 10 Years
Min: 0.96  Med: 1.60 Max: 3.78
Current: 2.73
0.96
3.78
PFCF 25.26
ABT's PFCF is ranked higher than
68% of the 205 Companies
in the Global Medical Devices industry.

( Industry Median: 34.47 vs. ABT: 25.26 )
Ranked among companies with meaningful PFCF only.
ABT' s PFCF Range Over the Past 10 Years
Min: 4.38  Med: 8.87 Max: 32.72
Current: 25.26
4.38
32.72
POCF 16.65
ABT's POCF is ranked higher than
65% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 19.47 vs. ABT: 16.65 )
Ranked among companies with meaningful POCF only.
ABT' s POCF Range Over the Past 10 Years
Min: 3.81  Med: 6.62 Max: 22.89
Current: 16.65
3.81
22.89
EV-to-EBIT 17.57
ABT's EV-to-EBIT is ranked higher than
54% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 24.10 vs. ABT: 17.57 )
Ranked among companies with meaningful EV-to-EBIT only.
ABT' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.4  Med: 10.00 Max: 108.7
Current: 17.57
5.4
108.7
EV-to-EBITDA 12.10
ABT's EV-to-EBITDA is ranked higher than
54% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 16.11 vs. ABT: 12.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 7.10 Max: 22.5
Current: 12.1
4.3
22.5
Shiller P/E 13.21
ABT's Shiller P/E is ranked higher than
93% of the 72 Companies
in the Global Medical Devices industry.

( Industry Median: 31.42 vs. ABT: 13.21 )
Ranked among companies with meaningful Shiller P/E only.
ABT' s Shiller P/E Range Over the Past 10 Years
Min: 9.07  Med: 12.33 Max: 18.04
Current: 13.21
9.07
18.04
Current Ratio 1.82
ABT's Current Ratio is ranked lower than
69% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.66 vs. ABT: 1.82 )
Ranked among companies with meaningful Current Ratio only.
ABT' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.38 Max: 2.36
Current: 1.82
0.75
2.36
Quick Ratio 1.51
ABT's Quick Ratio is ranked lower than
62% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ABT: 1.51 )
Ranked among companies with meaningful Quick Ratio only.
ABT' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 1.09 Max: 2.07
Current: 1.51
0.55
2.07
Days Inventory 92.71
ABT's Days Inventory is ranked higher than
70% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 142.23 vs. ABT: 92.71 )
Ranked among companies with meaningful Days Inventory only.
ABT' s Days Inventory Range Over the Past 10 Years
Min: 76.02  Med: 90.27 Max: 131.57
Current: 92.71
76.02
131.57
Days Sales Outstanding 61.89
ABT's Days Sales Outstanding is ranked higher than
61% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 72.25 vs. ABT: 61.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.44  Med: 70.94 Max: 129.28
Current: 61.89
58.44
129.28
Days Payable 42.02
ABT's Days Payable is ranked lower than
66% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 59.85 vs. ABT: 42.02 )
Ranked among companies with meaningful Days Payable only.
ABT' s Days Payable Range Over the Past 10 Years
Min: 35.38  Med: 39.77 Max: 66.81
Current: 42.02
35.38
66.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.64
ABT's Dividend Yield is ranked higher than
79% of the 189 Companies
in the Global Medical Devices industry.

( Industry Median: 1.72 vs. ABT: 2.64 )
Ranked among companies with meaningful Dividend Yield only.
ABT' s Dividend Yield Range Over the Past 10 Years
Min: 1.41  Med: 5.10 Max: 7.9
Current: 2.64
1.41
7.9
Dividend Payout 0.56
ABT's Dividend Payout is ranked higher than
96% of the 122 Companies
in the Global Medical Devices industry.

( Industry Median: 0.34 vs. ABT: 0.56 )
Ranked among companies with meaningful Dividend Payout only.
ABT' s Dividend Payout Range Over the Past 10 Years
Min: 0.16  Med: 0.47 Max: 2.53
Current: 0.56
0.16
2.53
Dividend Growth (3y) -22.40
ABT's Dividend Growth (3y) is ranked lower than
80% of the 64 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. ABT: -22.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
ABT' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -31.2  Med: 9.20 Max: 12.4
Current: -22.4
-31.2
12.4
Forward Dividend Yield 2.80
ABT's Forward Dividend Yield is ranked higher than
82% of the 176 Companies
in the Global Medical Devices industry.

( Industry Median: 1.76 vs. ABT: 2.80 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.10
ABT's Yield on cost (5-Year) is ranked lower than
68% of the 189 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. ABT: 1.10 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.59  Med: 2.12 Max: 3.28
Current: 1.1
0.59
3.28
3-Year Average Share Buyback Ratio 0.90
ABT's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: -4.30 vs. ABT: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: 0.00 Max: 0.9
Current: 0.9
-0.8
0.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.04
ABT's Price/Tangible Book is ranked lower than
70% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 4.04 vs. ABT: 10.04 )
Ranked among companies with meaningful Price/Tangible Book only.
ABT' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.1  Med: 8.77 Max: 427.67
Current: 10.04
3.1
427.67
Price/Projected FCF 0.86
ABT's Price/Projected FCF is ranked higher than
86% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. ABT: 0.86 )
Ranked among companies with meaningful Price/Projected FCF only.
ABT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.51  Med: 0.87 Max: 1.96
Current: 0.86
0.51
1.96
Price/Median PS Value 1.68
ABT's Price/Median PS Value is ranked lower than
86% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. ABT: 1.68 )
Ranked among companies with meaningful Price/Median PS Value only.
ABT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.61  Med: 1.08 Max: 2.24
Current: 1.68
0.61
2.24
Price/Graham Number 3.15
ABT's Price/Graham Number is ranked lower than
61% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. ABT: 3.15 )
Ranked among companies with meaningful Price/Graham Number only.
ABT' s Price/Graham Number Range Over the Past 10 Years
Min: 1.17  Med: 2.39 Max: 19.89
Current: 3.15
1.17
19.89
Earnings Yield (Greenblatt) (%) 5.70
ABT's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. ABT: 5.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.9  Med: 10.00 Max: 18.5
Current: 5.7
0.9
18.5
Forward Rate of Return (Yacktman) (%) -8.89
ABT's Forward Rate of Return (Yacktman) (%) is ranked lower than
78% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 5.28 vs. ABT: -8.89 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ABT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -12.5  Med: 16.40 Max: 29.8
Current: -8.89
-12.5
29.8

More Statistics

Revenue(Mil) $20405
EPS $ 2.92
Beta1.51
Short Percentage of Float1.15%
52-Week Range $36.00 - 51.74
Shares Outstanding(Mil)1491.72

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 20,507 21,568 22,664
EPS($) 2.15 2.43 2.64
EPS without NRI($) 2.15 2.43 2.64

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Devices » Medical Devices
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:ABT.Argentina, ABTT34.Brazil, ABT.Chile, ABL.Germany, ABT.Mexico, ABT.Switzerland, ABT.UK,
Abbott Laboratories is an Illinois corporation, incorporated in 1900. The Company discovers, develops, manufactures and sells health care products. Its services are sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies internationally. Its segments are Established Pharmaceutical Products, Nutritional Products, Diagnostic Products and Vascular Product. The Established Pharmaceutical Products is engaged in the International sales of various branded generic pharmaceutical products. Nutritional Products sells broad line of adult and pediatric nutritional products internationally. Diagnostic Products sells diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. This segment also includes Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions. Vascular Products sells coronary, endovascular, structural heart, vessel closure and other medical device products.
» More Articles for ABT

Headlines

Articles On GuruFocus.com
Valeant's Share Price Continues to Decline Feb 05 2016 
Abbott a Dividend Aristocrat Stock Propelled by Emerging Markets Dec 11 2015 
Baxalta Vs. AbbVie: Biopharma Spin-Off Battle Aug 20 2015 
Profit from Emerging Market Health Care Growth With Abbott Laboratories Jul 25 2015 
Becton and Dickinson: A Long-Term Bet Jul 08 2015 
Mason Hawkins Comments on Abbott Laboratories May 28 2015 
Endo International Posts Upbeat Q1 Results May 13 2015 
How Much Money Will You Need To Retire? Mar 31 2015 
Top Stock Picks Among Companies That Recently Increased Dividends Mar 09 2015 
Endo International Shares Upbeat After Positive Q4 Earnings Report Mar 03 2015 

More From Other Websites
Alere–Abbott Labs Is a Large, Strategic Deal for Arbitrageurs Feb 13 2016
Can Zoetis (ZTS) Keep the Earnings Streak Alive in Q4? Feb 12 2016
Mylan to buy Sweden's Meda AB for $7.2 billion Feb 10 2016
Mylan to buy Sweden's Meda AB for $7.2 billion Feb 10 2016
How Did Boston Scientific’s Stock Move after Its 4Q15 Earnings Release? Feb 10 2016
New Strong Sell Stocks for February 10th Feb 10 2016
The Alere-Abbott Labs Merger: Understanding the Alere Side Feb 09 2016
Abbott Introduces New 'Foodie' Inspired Snack Brand: Curate Feb 09 2016
Abbott Brings ‘Salted Decadence’ Bars to Crowded Snack Aisle Feb 09 2016
Extra Space Storage, Abbott Laboratories, First Data, ServiceMaster Global Holdings and ABM... Feb 08 2016
Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal... Feb 08 2016
Looking Into the Price Movements - Consensus Reports on Astrazeneca, Abbott Laboratories, Keurig... Feb 08 2016
Bear of the Day: Abbott Labs (ABT) Feb 08 2016
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of... Feb 04 2016
​Alere executives stand to reap $24M in payouts with Abbott buyout Feb 04 2016
Rationale for the Alere–Abbott Laboratories Merger Feb 04 2016
Abbott Labs Beefs Up Its Diagnostics Portfolio with Alere Feb 04 2016
Abbott Laboratories Posts Weak Guidance for 2016 Feb 04 2016
Abbott Established Pharmaceuticals: Impact of Currency Headwinds Feb 04 2016
What Makes Abbott Laboratories (ABT) a Strong Sell? Feb 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK